PD
ADVM

Point72 (DIFC)’s Adverum Biotechnologies ADVM Stock Holding History

Point72 (DIFC)’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-225
Closed -$484 – 1134
2025
Q2 		$484 Buy
+225
New +$629 ﹤0.01% 1464

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Point72 (DIFC)'s ADVM Position: Q3 2025 in Review

Point72 (DIFC) sold out of Adverum Biotechnologies (ADVM) in Q3 2025, closing a stake of 225 shares — an estimated $484 sold.

Point72 (DIFC) first reported a position in ADVM in Q2 2025 and held it in 1 quarter. The position peaked at $484 in Q2 2025. 50 funds tracked by Wall St. Rank hold ADVM as of Q3 2025.

  • Point72 (DIFC) reported no remaining Adverum Biotechnologies position as of Q3 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 225 Adverum Biotechnologies shares in Q3 2025, an estimated $484.
  • Point72 (DIFC) first reported a position in Adverum Biotechnologies in Q2 2025 and held it in 1 quarter.
  • Point72 (DIFC)'s Adverum Biotechnologies position peaked at $484 in Q2 2025.
  • 50 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.